The effect of TNF-α inhibitors, such as infliximab, etanercept, and adalimumab, in atherosclerosis has been evaluated in preclinical studies or in patients with rheumatological diseases where they have shown anti-inflammatory properties [142]. Here, TNF is linked to atherosclerosis.